O-1602 Catalog No.:M22717-C InChi: InChI=1S/C21H18O12/c22-9-2-1-7(3-10(9)23)13-6-12(25)15-11(24)4-8(5-14(15)32-13)31-21-18(28)16(26)17(27)19(33-21)20(29)30/h1-6

InChi: InChI=1S/C21H18O12/c22-9-2-1-7(3-10(9)23)13-6-12(25)15-11(24)4-8(5-14(15)32-13)31-21-18(28)16(26)17(27)19(33-21)20(29)30/h1-6

The number of autophagic vacuoles increases dramatically in the HAE and HPE groups after EIPA treatment compare with the HAN and HPN groups

InChiKey: TWHZNAUBXFZMCA-SCPKHUGHSA-N

InChiKey: UFKLYTOEMRFKAD-SHTZXODSSA-N

O-1602 Catalog No.:M22717-C InChi: InChI=1S/C21H18O12/c22-9-2-1-7(3-10(9)23)13-6-12(25)15-11(24)4-8(5-14(15)32-13)31-21-18(28)16(26)17(27)19(33-21)20(29)30/h1-6O 1602 is an agonist of GPR55 (EC50 = 13 nM in a GTPS binding assay) and a derivative of the GPR55 agonist abnormal cannabidiol. It is selective for GPR55 over cannabinoid (CB) receptor 1 (CB1) and CB2 (EC50s = >30 M for both in GTPS binding assays). O 1602 (50 M) reduces growth of Mz ChA 1, HuCCT 1, CC LP 1, and SG231 cholangiocarcinoma cells and reduces tumor growth in a Mz ChA 1 mouse xenograft model when administered at a dose of 10 mg kg per day.